Determination of Anti-Mullerian hormone status as an additional biomarker for diagnosis of polycystic ovary syndrome

Abstract

Background: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in adolescents and women of reproductive age and AMH (Anti-Mullerian Hormone) is an important hormonal indicator of PCOS. Methods: This was a cross-sectional type of comparative study on 80 reproductive women attending in the OPD of Obstetrics and Gynecology, Rajshahi medical college Hospital, Rajshahi over a period of 1 year from July 2021 to June 2022. Among them 40 PCOS women were selected in group A and 40 age matched healthy women were also recruited in group B for comparison. History of oligomenorrhoea, hirsutism, BMI and serum AMH level were estimated using the auto analyzer machine. Results: Mean AMH of PCOS and healthy women were 9.89 ± 3.84 mg/dl and 1.36 ± 1.05 mg/dl, respectively. In the study, the common phenotype of PCOS was phenotype C (40%) but highest mean level of AMH was found in phenotype B which was 12.7 ± 6.6 ng/ml. AMH was nine times higher in women with PCOS than healthy women and it was statistically highly significant (p < 0.001). Maximum diagnostic potential for PCOS was at cut-off 2.55 ng/ml with sensitivity 90% and specificity 85%. Conclusions: As a diagnostic tool, AMH is highly sensitive and specific in case of PCOS.